

# MYELOMA CLINICAL TRIALS

Data Driven Individualized Treatments for every patient - Pathway towards cure



Issue #1

MCT-Myeloma Clinical Trials LLC  
445 Park Avenue, 9th Floor New York, NY, 10022 Tel: 1-212-634-7914

## MCT Analytics

Visitors by Location

United States	Greece
United Kingdom	Singapore
Canada	Argentina
India	Colombia
China	Denmark
Germany	Taiwan
Japan	Philippines
France	Israel
Turkey	Austria
Italy	Sweden
Australia	Poland
Brazil	Norway
Korea, Republic of	Ireland
Spain	Romania
Hong Kong	Macedonia
Belgium	Portugal
Netherlands	Chile
Switzerland	Vietnam



Creating the world's most comprehensive database for Multiple Myeloma Clinical Trials.

Twitter: @MMTrials #mmsm #MultipleMyeloma #CureMyeloma

[WWW.THEMYELOMACLINICALTRIALS.COM](http://WWW.THEMYELOMACLINICALTRIALS.COM)

## The passion to pursue excellence in treatment of Multiple Myeloma.

### Mission Statement

To provide a seamless source of information for patients and caregivers all around the world to learn more about Multiple Myeloma and treatment options available including enrollment in Clinical trials.

To provide answers to frequently asked questions that arise during this journey and to empower patients and family members with knowledge through trusted sources in their fight against cancer.

To provide a useful resource for community oncologists involved in treating Myeloma patients to formulate Data Driven Individualized Treatment plans for patients, aiming for longer remissions, and turning remissions into cure.

To work in collaboration with Myeloma community organizations towards one common goal: CURE MYELOMA

After 5 years of treating Myeloma Patients at Mount Sinai NYC, Afshan Malik, MD, Myeloma Oncologist from New York City created MCT, a free global education platform for the myeloma community.

MCT Multiple Myeloma Clinical Trials ([themyelomaclinicaltrials.com](http://themyelomaclinicaltrials.com)) was established in late 2021 with a goal of creating the most comprehensive database for myeloma clinical trials, to deliver accurate and current information on all myeloma clinical trials.

MCT's database is growing since its launch, now including over 400 Myeloma Clinical Trials. MCT appears in search results for top Myeloma trials in all search engines like Google and Bing. 1300 unique visitors explored MCT in August 2022.

MCT is rapidly growing popularity in Multiple Myeloma Community, due to the wealth of information in easy to search format.

MCT provides a great resource tool for Myeloma community, patients, and caregivers as well as residents/fellows and community oncologists to research Multiple Myeloma Clinical trials.

Increased clinical trial education will result in a greater number of myeloma patients enrolling in clinical trials. Together, as the Myeloma Community, this will help us find cure for myeloma.

**Newly Diagnosed MM**  
146 Clinical Trials

[NDMM Trials | Myeloma Trials  
\(themyelomaclinicaltrials.com\)](http://themyelomaclinicaltrials.com)

**Relapsed & Refractory MM**  
295 Clinical Trials

[RRMM Trials | Myeloma Trials  
\(themyelomaclinicaltrials.com\)](http://themyelomaclinicaltrials.com)

**MGUS & Smoldering MM**  
34 Clinical Trials


[MGUS/SMM Trials | Myeloma Trials  
\(themyelomaclinicaltrials.com\)](http://themyelomaclinicaltrials.com)

# MCT's Most popular posts - August 2022

Visitor's top picks



19th International Myeloma Society Annual Meeting; Aug 25-27, LA California  
**#IMS2022**



NCT04923893: Phase 3 - VRd followed by Cilta-cel Vs VRd f/b Rd - NDMM- (No ASCT planned)  
**CARTITUDE-5**




NCT05083169: Phase 3 - Tec-Dara Vs DPd Vs DVd in Relapsed or Refractory Myeloma  
**MajesTEC-3**



What are Multiple myeloma defining events? International Myeloma Working Group - **SLiM-CRAB Criteria**



NCT05243797: Phase 3: Tec + Len Vs Len Alone in NDMM as Maintenance Therapy Post ASCT  
**MajesTEC-4**




NCT03652064 : Phase 3 - Bortezomib, Lenalidomide, Dex and +/- Daratumumab - NDMM  
**MMY3019 CEPHEUS**



NCT01208662- Phase 3 - Delayed vs Early Transplant with RVd & Revlimid Maint.  
**DETERMINATION Trial**



NCT03715478: Phase 1/2: Multi-Center Study of GSK2857916 With Pomalidomide & Dex  
**Algonquin trial**




NCT05020236: Phase 3: Elranatamab (PF-06863135) Vs & Elranatamab/Dara VS Dara/Pom/Dex  
**MagnetisMM-5**

# MCT's Most popular posts - August 2022

Visitor's top picks




**NCT04108195: Phase 1b - Subcutaneous Dara With Bispecific T Cell Redirection Antibodies**  
**TRIMM-2**




**NCT02874742: Phase 2 - Daratumumab, Len., Bortezomib & Dex (D-RVd) Vs (RVd) in New MM**  
**GRIFFIN**




**NCT03761108: Phase 1/2 - REGN5458 (Anti-BCMA x Anti-CD3 Bispecific Antibody) in Refractory MM**  
**LINKER-MM1**



**NCT04934475: Phase 3 - IFM 2020-02 Minimal Residual Disease Adapted Strategy KRd-Isatuximab**  
**MIDAS**



**NCT03710603: Phase 3 - Daratumumab, VELCADE, Len, Dex VS VELCADE, Len, Dex in NDMM**  
**(Perseus) EMN17**




**NCT04855136: Phase 1/2 - Safety and Efficacy of bb2121 (Ide-cel) Combinations in MM**  
**KarMMa-7**



**NCT03937635: Phase 3 - Lenalidomide, Dex +/- Daratumumab in High-Risk Smoldering Myeloma**  
**DETER-SMM**


## Featured Trials MGUS/SMM



**NCT04920084: A Study of a Plant-Based Diet in People With MGUS / Smoldering Myeloma**  
**NUTRIVENTION**




**NCT03689595: Predicting Progression of Developing MM in a High-Risk Screened Population**  
**PROMISE**



**The PCROWD Study** invites people with precursor conditions to Share samples a few times each year


## MCT Traffic Sources – August 2022



### Featured Myeloma Centers



### Featured Myeloma Conferences 2022



**Join us in creating the most comprehensive platform for Myeloma Clinical Trials**

[contact@mmeducation.org](mailto:contact@mmeducation.org)

